Does PeptiDream’s (TSE:4587) Phase 2 64Cu-PSMA-I&T Trial Redefine Its Radiopharma Ambitions?

• On October 15, 2025, PDRadiopharma Inc., PeptiDream Inc., and Curium Group announced the initiation of a registrational Phase 2 trial in Japan for 64Cu-PSMA-I&T, an innovative PET radiopharmaceutical imaging agent targeting prostate-specific membrane antigen in prostate cancer.
• This development strengthens the collaborative pipeline for advanced prostate cancer diagnostics and highlights increasing industry attention toward radiopharmaceuticals with both diagnostic and therapeutic applications.
• We'll examine how the launch of this registrational trial could reshape PeptiDream's investment narrative and clinical growth prospects.

Find companies with promising cash flow potential yet trading below their fair value.

PeptiDream Investment Narrative Recap

To be a PeptiDream shareholder, you must believe that its pipeline-driven innovation, especially in radiopharmaceuticals and peptide therapeutics, will translate into successful clinical progress, lucrative partnerships, and eventual profitability. The October 2025 initiation of the registrational Phase 2 trial for 64Cu-PSMA-I&T marks a potential positive for near-term clinical momentum, but it does not materially reduce PeptiDream’s reliance on the timing of major out-licensing deals, which remains the most immediate business risk.

Recent milestones, such as the first-in-human trial results for 64Cu-PD-32766 in clear cell renal cell carcinoma, reinforce PeptiDream’s broader capacity in radiopharmaceutical diagnostics and demonstrate continued clinical expansion. Each program’s progress helps diversify potential revenue streams but does not insulate the company from the cash flow risk if critical deals, like the myostatin program, face delays or hurdles. Contrasting these promising advances, investors should also be mindful of PeptiDream’s ongoing challenge with sustained operating losses and pressure on cash reserves…

Read the full narrative on PeptiDream (it's free!)

PeptiDream's narrative projects ¥53.3 billion in revenue and ¥16.1 billion in earnings by 2028. This requires 40.9% yearly revenue growth and an increase in earnings of ¥21.1 billion from the current ¥-5.0 billion.

Uncover how PeptiDream's forecasts yield a ¥3414 fair value, a 108% upside to its current price.

Exploring Other Perspectives

Private fair value estimates from the Simply Wall St Community span a wide range from ¥483 to ¥4,830 based on 2 analyses. While participants see the opportunity, PeptiDream’s path to profitability and reliance on timely out-licensing deals remain important to any outlook, so consider how your own expectations align with these views.

Explore 2 other fair value estimates on PeptiDream - why the stock might be worth less than half the current price!

Build Your Own PeptiDream Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your PeptiDream research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free PeptiDream research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate PeptiDream's overall financial health at a glance.

Ready For A Different Approach?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• The end of cancer? These 27 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 35 best rare earth metal stocks of the very few that mine this essential strategic resource.
• This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com